Skip to main content
OpenTrials

Clinical trial condition

Neuroendocrine Tumors

Explore clinical trials studying Neuroendocrine Tumors. Study availability and eligibility vary by location and protocol.

2,766 public trials 495 recruiting studies
Refine in advanced search Browse all conditions

Neuroendocrine Tumors trial results

Active, Not Recruiting

Neoadjuvant L19IL2/L19TNF- Pivotal Study

NCT02938299

Conditions
Malignant Melanoma, Melanoma, Neoplasms, +10 more
Locations
  • Hôpital de la Timone Marseille, France
  • Hôpital Universitaire de Nantes Nantes, France
  • Institut Gustave Roussy Villejuif, France
  • Universitätsklinikum Carl Gustav Carus an der Technischen Universität Dresden Dresden, Germany
View all 22 locations
View Trial Details
Active, Not Recruiting

Spanish Study for Molecular Characterization of Thyroid Carcinoma

NCT04970134

Conditions
Adenocarcinoma, Carcinoma, Carcinoma, Medullary, +11 more
Locations
  • Hospital Universitario Vall d'Hebron Barcelona, Spain
  • Hospital Clínic de Barcelona Barcelona, Spain
  • Hospital Universitario Durán i Reinals L'Hospitalet de Llobregat, Barcelona, Spain
  • Fundació Althaia Manresa, Barcelona, Spain
View Trial Details
Active, Not Recruiting

ENB003 Plus Pembrolizumab Phase 1b/2a in Solid Tumors

NCT04205227

Conditions
Adnexal Diseases, Cancer, Digestive System Diseases, +30 more
Locations
  • Cedars Sinai-The Angeles Clinic Los Angeles, California, United States
  • MD Anderson Cancer Center Houston, Texas, United States
  • Border Medical Oncology Albury, New South Wales, Australia
  • Blacktown Oncology Blacktown, New South Wales, Australia
View Trial Details
Active, Not Recruiting

A RC198 Study in Subjects With Locally Advanced Unresectable or Metastatic Solid Tumors

NCT05867303

Conditions
Adenocarcinoma, Bronchial Neoplasms, Carcinoma, +48 more
Locations
  • ICON Cancer Centre Wesley Auchenflower, Queensland, Australia
  • Southern Oncology Clinical Research Unit Bedford Park, South Australia, Australia
  • Cabrini Hospital Malvern Malvern, Victoria, Australia
  • Sun Yat-sen University Cancer Center Guangzhou, Guangdong, China
View Trial Details
Active, Not Recruiting

Study of Zirconium Zr 89 Crefmirlimab Berdoxam PET/CT in Subjects With Advanced or Metastatic Malignancies

NCT05013099

Conditions
Adenocarcinoma, Bronchial Neoplasms, Carcinoma, +40 more
Locations
  • CARTI Cancer Center Little Rock, Arkansas, United States
  • City of Hope Duarte, California, United States
  • Providence Saint John's Cancer Institute Santa Monica, California, United States
  • Memorial Sloan Kettering Cancer Center New York, United States
View all 16 locations
View Trial Details
Active, Not Recruiting

Adjuvant Nivolumab Treatment in Stage II (IIA, IIB, IIC) High-risk Melanoma

NCT04309409

Conditions
Malignant Melanoma Stage II, Melanoma, Neoplasms, +10 more
Locations
  • Universitätsklinikum Würzburg - Klinik für Dermatologie, Venerologie und Allergologie Würzburg, Bavaria, Germany
  • Universitätsmedizin Rostock -Klinik und Poliklinik für Dermatologie und Venerologie Rostock, Mecklenburg-Vorpommern, Germany
  • Universitätsklinikum Augsburg, Campus Süd Augsburg, Germany
  • St. Josef-Hospital - Dermatologische Studienambulanz Bochum, Germany
View all 20 locations
View Trial Details
Active, Not Recruiting

Neoadjuvant Ipilimumab Plus Nivolumab Versus Standard Adjuvant Nivolumab in Macroscopic Stage III Melanoma

NCT04949113

Conditions
Malignant Melanoma Stage III, Melanoma, Neoplasms, +10 more
Locations
  • The Angeles Clinic Los Angeles, California, United States
  • MD Anderson Cancer Center Houston, Texas, United States
  • Melanoma Institute Australia (MIA) Sydney, New South Wales, Australia
  • Princess Alexandra Hospital Brisbane, Australia
View all 24 locations
View Trial Details
Active, Not Recruiting

An Open-Label Expanded Access Study of the Melphalan/Hepatic Delivery System (HDS) in Patients With Hepatic Dominant Ocular Melanoma

NCT05022901

Conditions
Eye Diseases, Eye Neoplasms, Melanoma, +13 more
Locations
  • Stanford Cancer Institute Palo Alto, California, United States
  • Moffitt Cancer Center Tampa, Florida, United States
  • Duke University Medical Center Durham, North Carolina, United States
  • The Ohio State University Columbus, Ohio, United States
View Trial Details

Related conditions